Market Overview

UPDATE: Sterne Agee Downgrades PAREXEL Following FY13 Results, FY14 Guidance

Share:
Related PRXL
Exclusive: Dr. Ron Farkas, Eteplirsen's Harshest Critic, Has Left The FDA
10 Biggest Mid-Day Losers For Tuesday
PAREXEL to acquire functional service provider (Seeking Alpha)

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan downgraded PAREXEL (NASDAQ: PRXL) from Neutral to Underperform, and lowered the price target from $44.00 to $36.00.

In the report, Sterne Agee noted, “After rigorous yet straightforward analyses, we conclude that PRXL's FY13 results were inflated by several favorable, non-fundamental variables and that FY14 operating margin guidance appears aggressive. We also conclude that with the expected moderation of revenue contribution from PRXL's largest client, upside to FY14 revenue guidance may be limited. Downgrading to Underperform and establishing a $36 price target based on 16x our CY15 EPS estimate of $2.36.”

PAREXEL closed on Tuesday at $51.33.

Latest Ratings for PRXL

DateFirmActionFromTo
Sep 2016UBSDowngradesBuyNeutral
Aug 2016JefferiesMaintainsHold
Aug 2016Deutsche BankMaintainsHold

View More Analyst Ratings for PRXL
View the Latest Analyst Ratings

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Downgrades Analyst Ratings

 

Related Articles (PRXL)

View Comments and Join the Discussion!